← Back to Clinical Trials
Recruiting NCT04602481

NCT04602481 Living With Primary Ciliary Dyskinesia (Living With PCD)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04602481
Status Recruiting
Phase
Sponsor University of Bern
Condition Primary Ciliary Dyskinesia
Study Type OBSERVATIONAL
Enrollment 1,500 participants
Start Date 2020-05-31
Primary Completion 2030-05-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,500 participants in total. It began in 2020-05-31 with a primary completion date of 2030-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Living with PCD (formerly COVID-PCD) is a participatory research project that aims to answer emerging questions about primary ciliary dyskinesia (PCD) in order to improve the health and quality of life of people with PCD. Persons with confirmed or suspected PCD from anywhere in the world can participate. The study is advertised through patient support groups and participants register online after they read detailed information about the study. Participants receive a detailed questionnaire when they start the study and a follow-up questionnaire (planned once per year). Occasionally, participants receive extra questionnaires focused on special topics. The study is hosted at the University of Bern and recruitment started on May 30th, 2020.

Eligibility Criteria

Inclusion Criteria: * People of any age with reported suspected or confirmed Primary Ciliary Dyskinesia who gave consent to participate in the study Exclusion Criteria: * People who report not to have suspected or confirmed Primary Ciliary Dyskinesia

Contact & Investigator

Central Contact

Claudia E Kuehni, Prof.

✉ claudia.kuehni@unibe.ch

📞 +41 31 684 35 07

Principal Investigator

Claudia E Kuehni, Prof.

PRINCIPAL INVESTIGATOR

University of Bern

Frequently Asked Questions

Who can join the NCT04602481 clinical trial?

This trial is open to participants of all sexes, studying Primary Ciliary Dyskinesia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04602481 currently recruiting?

Yes, NCT04602481 is actively recruiting participants. Contact the research team at claudia.kuehni@unibe.ch for enrollment information.

Where is the NCT04602481 trial being conducted?

This trial is being conducted at Bern, Switzerland.

Who is sponsoring the NCT04602481 clinical trial?

NCT04602481 is sponsored by University of Bern. The principal investigator is Claudia E Kuehni, Prof. at University of Bern. The trial plans to enroll 1,500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology